Pilot Study to Identify the Mechanism of De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) in NSCLC With EGFR Mutation.
Investigators will prospectively enroll patients who match the following criteria:
pathologically proven unresectable NSCLC, planning to treat with EGFR-TKI, patients with
activating EGFR mutations, and available tissue sample for DNA extraction.
Time Perspective: Prospective
hazard rates of PFS
The primary objective is to compare hazard rates of PFS in patients treated with Iressa between with and without any molecular aberrancy in EGFR-downstream genes/proteins.
Joo Hang Kim, MD, PhD
Korea: Food and Drug Administration